About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Forecasting the prevalence of status epilepticus and ist subtypes in Europe, 2015-2024


To estimate the prevalence of status epilepticus (SE), refractory status epilepticus (RSE), and super-refractory status epilepticus (SRSE) in five major European Union (5EU) markets (France, Germany, Italy, Spain, and the UnitedKingdom) using an incidence-survival model.


Yearly survival data for each SE etiology (acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/cryptogenic) were extracted from published research. Incident cases were calculated for each etiology beginning with 1995, based on market-specific published rates. Applying the survival proportions and incidence estimates to the model for each etiology, we calculated an overall estimate of the prevalence of SE. RSE and SRSE prevalent cases were assessed as proportions of the total number of prevalent SE cases using published values.


We estimated the prevalence of SE to be 18.4 cases per 10,000 population in the5EU, resulting in 590,264 cases in 2015 and increasing to 603,951 in 2024. The calculated prevalence ranged from 17.2 cases per 10,000 (Germany) to 19.7 cases per 10,000 (Italy). The prevalence of RSE in the 5EU was 4.5 per 10,000, resulting in 145,205 cases in 2015, increasing to 148,572 in 2024. SRSE prevalence in the 5EU was 1.8 per 10,000, resulting in 59,027 cases in 2015, increasing to 60,395 in 2024.


To our knowledge, this is the first attempt to calculate the prevalence of SE and its subtypes for all ages in Europe. Estimating the prevalence of SE, RSE, and SRSE using population-based epidemiological methods is challenging because of the variability of SE disease definitions and the unpredictable nature of mortality due to SE. Our incidence-survival model provides an alternative and effective method to assess the prevalent population. Considering the high costs associated with treatment and hospitalization of SE, RSE, and SRSE patients, these estimates are necessary to quantify the burden of disease in Europe.